Pharming Group (OTCMKTS:PHGUF) Announces Quarterly Earnings Results

Pharming Group (OTCMKTS:PHGUF) released its quarterly earnings results on Thursday. The biotechnology company reported $0.01 EPS for the quarter, Zacks reports. The firm had revenue of $97.30 million for the quarter, compared to analyst estimates of $80.18 million. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%.

Pharming Group Price Performance

Pharming Group stock traded up $0.33 during midday trading on Thursday, hitting $1.53. 2,400 shares of the company were exchanged, compared to its average volume of 8,527. The company’s fifty day moving average price is $1.47 and its 200-day moving average price is $1.22. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.07 and a current ratio of 2.79. Pharming Group has a fifty-two week low of $0.75 and a fifty-two week high of $1.53.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.